QuantRX Biomedical (QTXB) Stock Price, News & Analysis

Company Overview

QuantRX Biomedical, Inc. (OTCMKTS: QTXB) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for central nervous system disorders and pain management. Headquartered in Miami, Florida, the company focuses on leveraging advanced drug‐delivery platforms and nanoparticle technologies to improve the efficacy and safety profiles of established active pharmaceutical ingredients. QuantRX maintains in-house research and development laboratories and collaborates with contract research organizations in North America and Europe to accelerate preclinical and clinical programs.

The company’s primary business activities center on two lead programs: a controlled-release formulation aimed at attention‐deficit/hyperactivity disorder (ADHD) and a sustained-release analgesic designed for chronic pain relief. QuantRX applies a proprietary liposomal delivery platform to achieve targeted release kinetics, reduce systemic side effects and extend dosing intervals. In addition to its core pipeline, the company is exploring opportunistic licensing partnerships to broaden its therapeutic portfolio into additional CNS indications.

Founded in 2017 by a team of serial entrepreneurs and ex-pharma executives, QuantRX Biomedical has steadily advanced its pipeline through preclinical milestones and early-phase clinical studies. The company’s research efforts are supported by collaborations with several European contract research organizations, and it has engaged with regulatory authorities in both the United States and the United Kingdom. QuantRX also maintains a small strategic alliance in Asia to explore formulation scale-up and manufacturing opportunities.

QuantRX’s leadership team is chaired by CEO Dr. Michael Harris, a veteran drug developer with over two decades of experience in pharmaceutical R&D and regulatory affairs. Chief Scientific Officer Dr. Sarah Williams oversees the company’s pipeline strategy, while Chief Financial Officer Linda Chen directs corporate finance and investor relations. Supported by an advisory board of industry veterans, QuantRX Biomedical continues to advance its proprietary technology toward later‐stage clinical development.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QTXB Stock Analysis - Frequently Asked Questions

How do I buy shares of QuantRX Biomedical?

Shares of QTXB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QuantRX Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QuantRX Biomedical investors own include Augusta Gold (AUGG), Cannabis Wheaton Income (CBWTF), Christopher & Banks (CBK), Babcock (BW), Ascent Solar Technologies (ASTI), Arch Therapeutics (ARTH) and Amerigo Resources (ARREF).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:QTXB
• CIK: 820608
• Web: www.quantrx.com
• Phone: (212) 980-2235
• Fax: 1-267-880-1596
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A